Wollschlaeger Bernd A, Willson Tina M, Montejano Leslie B, Ronquest Naoko A, Nadipelli Vijay R
Physician, Aventura Family Health Center, North Miami Beach, Florida.
Senior Research Analyst, Truven Health Analytics Inc., an IBM Company, Cambridge, Massachusetts; Now Data Manager III with Division of Epidemiology, University of Utah, Salt Lake City, Utah.
J Opioid Manag. 2017 Jul/Aug;13(4):207-220. doi: 10.5055/jom.2017.0389.
To identify the demographic and clinical characteristics of commercially insured and Medicaid patients with a diagnosis of opioid dependence or abuse and to describe the pharmacological and nonpharmacological treatments received by these patients.
This was a retrospective observational study using de-identified administrative claims data.
The analysis included commercially insured and Medicaid patient data extracted from the Truven Health MarketScan® Commercial and Medicaid Databases.
Patients with a diagnosis of opioid dependence or abuse from 2008 to 2014 (earliest diagnosis = index date) and a minimum of 6 months of pre-index and postindex continuous enrollment in the database.
MAIN OUTCOME MEASURE(S): Baseline demographic and clinical characteristics, medication-assisted treatment (MAT), and treatment other than MAT received following diagnosis, and the clinical practice setting in which patients received any opioid dependence-related care were reported.
Data from commercially insured (N = 103,768) and Medicaid (N = 50,552) patients were analyzed. Common comorbid conditions included chronic pain (48.6 percent Commercial, 56.8 percent Medicaid), depressive disorder (24.0 percent Commercial, 32.8 percent Medicaid), and other substance abuse disorders (13.3 percent Commercial, 23.7 percent Medicaid). Nearly one third of both Commercial (31.6 percent) and Medicaid (33.6 percent) patients did not have any claims for psychosocial therapy or MAT during the follow-up period. Only 24.3 percent of Commercial patients and 20.4 percent of Medicaid patients had evidence of claims for both MAT and psychosocial treatment anytime following diagnosis.
The results suggest that there are opportunities to improve care through comprehensive and coordinated treatment for opioid dependence/abuse. Policies aimed at improving treatment access may be warranted.
确定诊断为阿片类药物依赖或滥用的商业保险患者和医疗补助患者的人口统计学和临床特征,并描述这些患者接受的药物和非药物治疗。
这是一项使用去识别化行政索赔数据的回顾性观察研究。
分析包括从Truven Health MarketScan®商业和医疗补助数据库中提取的商业保险患者和医疗补助患者数据。
2008年至2014年诊断为阿片类药物依赖或滥用的患者(最早诊断日期 = 索引日期),且在数据库中索引日期之前和之后至少连续登记6个月。
报告基线人口统计学和临床特征、药物辅助治疗(MAT)、诊断后接受的MAT以外的治疗,以及患者接受任何阿片类药物依赖相关护理的临床实践环境。
分析了商业保险患者(N = 103,768)和医疗补助患者(N = 50,552)的数据。常见的合并症包括慢性疼痛(商业保险患者中占48.6%,医疗补助患者中占56.8%)、抑郁症(商业保险患者中占24.0%,医疗补助患者中占32.8%)和其他物质滥用障碍(商业保险患者中占13.3%,医疗补助患者中占23.7%)。在随访期间,近三分之一的商业保险患者(31.6%)和医疗补助患者(33.6%)没有任何心理社会治疗或MAT的索赔记录。在诊断后的任何时候,只有24.3%的商业保险患者和20.4%的医疗补助患者有MAT和心理社会治疗的索赔证据。
结果表明,通过对阿片类药物依赖/滥用进行全面和协调的治疗,有机会改善护理。可能有必要制定旨在改善治疗可及性的政策。